axicabtagene ciloleucel,Mosunetuzumab,Glofitamab
gilead,roche
['lymsm', 'axi-cel', 'cml']
regarding bites &amp; car, survival curves for mosun, glofit, and axi-cel all suggest a possible plateau (cure?) with longer follow-up, especially for patients who achieve a cr. #lymsm #celltherapy #17icml 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈